The city of St. Petersburg on Friday opened two metro stations that form the initial segment of a new metro line. The ...

No one's crossed the finishing line yet, but drug developer Nyrada is leading the Great Biotech Regatta of 2025 with close to ...

China NMPA grants marketing approval for Innovent Biologics' Tyvyt, a CTLA-4 monoclonal antibody: San Francisco Saturday, December 27, 2025, 16:00 Hrs [IST] Innovent Biologics Inc ...

Firmonertinib has the potential to redefine first-line treatment in this underserved population as a once daily, oral, brain-penetrant, ...

In line with its expansion into institutional-grade infrastructure services, Crouton Digital has initiated the process of ...

Daiichi Sankyo &AstraZeneca’s Enhertu approved in China as first HER2 directed medicine for patients with HER2 low or HER2 ultralow metastatic breast cancer ...

SoundHound AI's recent financial performance has been impressive. In the first nine months of fiscal 2025, revenue jumped 127% year over year to $114 million. While not yet profitable, management ...

The company plans to announce Phase 1b interim data by mid-2026, and the TENACITY-01 study is expected to be completed by late 2028. This timing enables progression to Phase 2 evaluation following ...

Galectin Therapeutics Inc. is rated a Hold due to absence of finalized agreement with FDA, combined with a tight runway. Read ...

The cellular therapy landscape continues to evolve beyond hematologic malignancies, now making significant progress in solid ...

Mustafa Suleyman, the former Google DeepMind co-founder who now leads Microsoft’s AI division, has spoken openly against the ...

On December 3, 2025, Compass Therapeutics, Inc. (NASDAQ:CMPX) saw Canaccord analyst John Newman initiate coverage of the ...